Zampilimab
- Generic Name
- Zampilimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2098280-42-1
- Unique Ingredient Identifier
- 52B38H09GZ
- Background
Zampilimab is under investigation in clinical trial NCT04335578 (A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of UCB7858 in Adult Kidney Transplant Recipients With Chronic Allograft Injury).
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Test Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of Zampilimab in Healthy Participants
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2022-07-19
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 16
- Registration Number
- NCT04705350
- Locations
- 🇬🇧
Up0105 001, London, United Kingdom
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zampilimab in Adult Kidney Transplant Recipients With Chronic Allograft Injury
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 3
- Registration Number
- NCT04335578
- Locations
- 🇧🇪
Cai001 101, Leuven, Belgium
🇬🇧Cai001 501, London, United Kingdom
🇪🇸Cai001 302, Hospitalet de Llobregat, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath